» Articles » PMID: 38765199

Differential Manifestations of Inflammatory Bowel Disease Based on Race and Immigration Status

Overview
Journal Gastro Hep Adv
Specialty Gastroenterology
Date 2024 May 20
PMID 38765199
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: The prevalence of inflammatory bowel disease (IBD) is increasing globally. In this context, identifying risk factors for severe disease is important. We examined how race/ethnicity and immigration status influence IBD manifestations, treatments, and outcomes in a diverse, tertiary-care safety-net hospital.

Methods: We conducted a single-center retrospective review of all IBD inpatients and outpatients treated from 1997-2017. Using logistic regression modeling, we compared disease onset, treatment, and outcomes by race (White, Black, Hispanic, or Asian) and immigration status (US-born vs foreign-born).

Results: A total of 577 patients were identified, of which 29.8% were White, 27.4% were Hispanic, 21.7% were Black, and 13.0% were Asian. Compared to Whites, Asians were more likely to be male (odds ratio [OR] 2.63, 95% confidence interval [CI]: 1.45, 5.00), whereas Blacks were more likely to be diagnosed with Crohn's disease (OR 1.75, 95% CI: 1.10, 2.77) and more likely to undergo IBD-related intestinal resection (OR 2.49, 95% CI: 1.40, 4.50). Compared to US-born patients, foreign-born patients were more likely to be diagnosed with ulcerative colitis (OR 1.77, 95% CI: 1.04, 3.02). They were also less likely to be diagnosed before 16 years of age (OR 0.19, 95% CI: 0.08, 0.41), to have undergone intestinal resections (OR 0.39, 95% CI: 0.19, 0.83), to have received biologics (OR 0.43, 95% CI: 0.25, 0.76), or to have had dermatologic manifestations (OR 0.12, 95% CI: 0.03, 0.41).

Conclusion: IBD phenotype varies by race, although foreign-born patients of all races show evidence of later-onset and milder disease. These findings may aid in disease prognostication and clinical management and, furthermore, may provide insight into intrinsic and environmental influences on IBD pathogenesis.

Citing Articles

Key Themes in the Care of Inflammatory Bowel Diseases Among Immigrant Populations: A Systematic Review.

Youssef M, Tandon P, Jones T, Srikanth V, Targownik L Dig Dis Sci. 2025; .

PMID: 39843786 DOI: 10.1007/s10620-024-08801-2.


Lupus and other autoimmune diseases: Epidemiology in the population of African ancestry and diagnostic and management challenges in Africa.

Essouma M, Noubiap J J Allergy Clin Immunol Glob. 2024; 3(4):100288.

PMID: 39282618 PMC: 11399606. DOI: 10.1016/j.jacig.2024.100288.


Racial and ethnic differences in diagnosis age and blood biomarkers in a pediatric inflammatory bowel disease cohort.

Kemp K, Nagaraj P, Orihuela C, Lorenz R, Maynard C, Pollock J J Pediatr Gastroenterol Nutr. 2024; 78(3):634-643.

PMID: 38284647 PMC: 11181309. DOI: 10.1002/jpn3.12131.

References
1.
Satsangi J, Silverberg M, Vermeire S, Colombel J . The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55(6):749-53. PMC: 1856208. DOI: 10.1136/gut.2005.082909. View

2.
Aniwan S, Tremaine W, Raffals L, Kane S, Loftus Jr E . Antibiotic Use and New-Onset Inflammatory Bowel Disease in Olmsted County, Minnesota: A Population-Based Case-Control Study. J Crohns Colitis. 2017; 12(2):137-144. PMC: 5881749. DOI: 10.1093/ecco-jcc/jjx135. View

3.
Jung Y, Han M, Kim W, Park S, Cheon J . Incidence and Clinical Outcomes of Inflammatory Bowel Disease in South Korea, 2011-2014: A Nationwide Population-Based Study. Dig Dis Sci. 2017; 62(8):2102-2112. DOI: 10.1007/s10620-017-4640-9. View

4.
Mangat B, Evaschen C, Lee T, Yoshida E, Salh B . Ethnic variation in the annual rates of adult inflammatory bowel disease in hospitalized patients in Vancouver, British Columbia. Can J Gastroenterol. 2011; 25(2):73-7. PMC: 3043007. DOI: 10.1155/2011/640920. View

5.
Perez-Jeldres T, Pizarro B, Ascui G, Orellana M, Cerda-Villablanca M, Alvares D . Ethnicity influences phenotype and clinical outcomes: Comparing a South American with a North American inflammatory bowel disease cohort. Medicine (Baltimore). 2022; 101(36):e30216. PMC: 10980497. DOI: 10.1097/MD.0000000000030216. View